New York, New York--(Newsfile Corp. - February 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2026.SO WHAT: If you purchased REGENXBIO securities during the Class Period y ...

Core Viewpoint - A class action lawsuit has been filed against REGENXBIO Inc. for allegedly providing misleading information regarding its gene therapy product RGX-111, leading to significant investor losses [2][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of Maryland on behalf of all individuals and entities who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026 [2]. - Investors have until April 14, 2026, to apply to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that REGENXBIO's management made positive assertions about RGX-111's trial success while concealing material adverse facts regarding its efficacy and safety [3]. - Following the announcement of a clinical hold by the FDA due to the discovery of an intraventricular CNS tumor in a trial participant, REGENXBIO's stock price fell from $13.41 to $11.01, a decline of 17.8% in one day [3]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the case are encouraged to contact the law firm for more details and assistance [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. due to allegations of violations of federal securities laws related to misleading statements about the efficacy and safety of its RGX-111 trial study [4][5]. Group 1: Legal Investigation - The firm is reminding investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against REGENXBIO [4]. - The investigation follows a press release from REGENXBIO on January 28, 2026, announcing a clinical hold by the FDA on its RGX-111 investigational gene therapy due to a case of neoplasm in a trial participant [6]. - Following the announcement, REGENXBIO's stock price dropped by $2.40 per share, or 17.9%, closing at $11.01 per share [6]. Group 2: Company Background - REGENXBIO is involved in gene therapy, specifically targeting conditions such as MPS I (Hurler syndrome) and MPS II (Hunter syndrome) [6]. - The firm has recovered hundreds of millions of dollars for investors since its founding in 1995, indicating a strong track record in securities law [5].

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2026. SO WHAT: If you purchased REGENXBIO securities during the Class Period you may be enti ...

ATLANTA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against REGENXBIO Inc. (NASDAQ: RGNX). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts concerning the efficacy and safety of its RGX-111 trial study, causing Plaintiff and other shareholders to purchase REGENXBIO’s securities at artificially inflated prices. If you purchased REGENXBIO shares between February 9, 2022 and January 27, 2026, an ...

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against REGENXBIO Inc. (NASDAQ: RGNX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired REGENXBIO securities between February 9, 2022 and January 27, 2026, both dat ...

LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises REGENXBIO, Inc., (“REGENXBIO” or the "Company") (NASDAQ: RGNX) investors of a class action on behalf of investors that bought securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO investors have until April 14, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal ...

LOS ANGELES--(BUSINESS WIRE)--REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – RGNX. ...

Core Viewpoint - A class action lawsuit has been initiated against REGENXBIO, Inc. for alleged securities fraud during the period from February 9, 2022, to January 27, 2026, with investors potentially entitled to compensation without upfront costs [1] Group 1: Lawsuit Details - The lawsuit claims that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I, also known as Hurler syndrome [1] - Defendants allegedly made positive assertions about RGX-111's trial success based on favorable biomarker and safety data while concealing adverse facts about the trial's efficacy and safety [1] - Investors reportedly suffered damages when the true details about the trial were revealed [1] Group 2: Legal Representation - Investors wishing to join the class action can do so without any out-of-pocket fees through a contingency fee arrangement [1] - The Rosen Law Firm, known for its success in securities class actions, encourages investors to select qualified counsel with a proven track record [1] - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 [1]

Core Viewpoint - Investors in REGENXBIO Inc. have the opportunity to lead a securities fraud lawsuit against the company due to alleged misleading statements regarding the efficacy and safety of its product candidate RGX-111 [1] Group 1: Lawsuit Details - The Schall Law Firm is reminding investors of a class action lawsuit against REGENXBIO Inc. for violations of the Securities Exchange Act of 1934 [1] - The class period for the lawsuit is defined as between February 9, 2022, and January 27, 2026 [1] - Investors who suffered losses during this period are encouraged to contact the Schall Law Firm before April 14, 2026 [1] Group 2: Allegations Against the Company - The complaint alleges that REGENXBIO made false and misleading statements about RGX-111 while concealing negative data regarding its efficacy and safety [1] - A significant issue arose when an intraventricular CNS tumor was discovered in a participant treated in the RGX-111 study, which contradicted the company's positive statements [1] - The lawsuit claims that the company's public statements were materially misleading throughout the class period, leading to investor damages when the truth was revealed [1]